RE:The mostly fools At this point, I will welcome any and all somewhat positive press, but this is just sad.
According to this we're now initiating a Phase III clinical trial to study tesamorelin for various types of cancer
Robust business strategy
The company plans on initiating a phase-three clinical trial to study tesamorelin for the treatment of various types of cancers. Theratechnologies’s business strategy is focused on increasing sales of EGRIFTA and Trogarzo in the United States. Further, the company plan to launch Trogarzo in key countries of the E.U. and obtain reimbursements for the product.